Page 5828 - Markets News

Markets flat in late noon deals; oil, IT majors surge

Metal, bank stocks show weakness, sugar shares trade in red

FinMin tightens grip on black money

Asset quality deterioration seen moderating in third quarter

Bankers sound a note of caution for Q4 ending March 2013 and beyond. The scenario is changing for the better but things will look up gradually

Essar Oil to swap rupee debt with dollar loans

Markets listless as focus shifts to Union Budget

Broader markets traded mixed with small-caps gaining nearly 0.4% in noon trades.

Pidilite Industries gains in noon deals

Stock up nearly 3%

Web Exclusive: Ten mid-cap & small-cap stocks one can buy

BSE mid-cap index up 0.16% to 6,740 levels, while the small-cap index has surged 0.62%, or 41 points, to 6,691 levels

FMC to allow market makers soon

Currently, on commodity exchanges, quote-driven system is prevalent in which traders provide one-way quote

Jaiprakash Power Ventures slump on news of equity dilution

Stock down 6% in noon deals

Markets trim gains on profit booking in FMCG shares

ICICI Bank and FMCG majors Hindustan Unilever, ITC among the top Sensex losers

F&O watch: RIL, Jet Airways, Suzlon

Check out the trading strategies for frontline and mid-cap stocks in the F&O segment with Shshank Mehta, derivatives strategist, Shah Investor's Home

Lanco Infratech moves up on stake sale talks

Stock gains 2%

Markets remain rangebound, broader markets outperform

BSE Oil & Gas, Realty and IT indices have surged by almost 1% each

Reliance Industries gains on investment plans in KG-D6 block

Stock up 2%

Markets positive tracking firm global cues, RIL top gainer

Upmove supported by the gains in US and Asian markets

Pre-market: Positive opening likely, world markets strong

Heavyweights - RIL, Bharti Airtel, Tata Motors in focus

Brokerage houses shy away from lateral hiring

Severe cost-cutting leads to fall in demand for graduates with work experience

On your mark, get set...

Sensex posts biggest daily gain since January 25

Pricing policy overhang to limit upside for GSK Pharma

Ability to maintain sales growth and hold on to margins are other critical areas to watch